| 摘要 |
<p>The present invention provides a method for monitoring the response to treatment in a patient undergoing ovarian cancer therapy, comprising detecting the presence of a loss-of-function-related genetic alteration in the PAPPA gene or its regulatory or promoter sequences in a sample obtained from the patient, wherein the presence of a genetic alteration and downward change in its quantitative levels is indicative of response to therapy, and wherein no change or upward change in its quantitative level is indicative of non-response to therapy. The invention also relates to the use of specific biological markers for detecting relapse after treatment, for staging spread of disease, and predicting disease progression.</p> |
